Merck heads to Ireland for new 200m site

By Anna Lewcock

- Last updated on GMT

Related tags: Ireland, Merck, Investment

Merck has settled on a site in south east Ireland for a new
vaccines and biologics facility, investing €200m ($280m) in its
third facility on the island.

The announcement was made earlier this week by Ireland's Industrial Development Agency (IDA), which heralded the news as a "very significant consolidation of Ireland's high profile position as a successful location for substantial biotechnology global investments."​ Merck has splashed out €200m to get it hands on the 65-acre IDA Business and Technology Park in Carlow, on which it plans to build its new facility. The plant itself will be Ireland's first stand-alone human vaccine project, and will involve a formulation and sterile filling facilities alongside R&D operations to support recently launched vaccines and future projects. According to the IDA, Merck also intends to tap the academic scene in Ireland to seek out opportunities in biologics. The plant is due to be up and running by 2011, employing 170 people across production, engineering, R&D, quality control, management and administration. Merck settled on the location after considering a number of sites worldwide, making this the company's third plant in the region. The existing operations fall under the remit of Merck, Sharp & Dohme, with construction on a new R&D and manufacturing facility in Tipperary having commenced last month. Merck is not alone in choosing to establish a number of sites in Ireland, with several pharma firms operating multiple sites in the region in response to considerable time and effort spent by the IDA and its counterparts to create an attractive environment for the sector. Abbott, for example, operates seven sites in Ireland, Johnson & Johnson has six, Pfizer currently has five and Schering Plough and GlaxoSmithKline both have four. Ireland has in fact become a real focal point for the industry, establishing itself as the most popular destination for development and manufacture outside the US, according to the IDA. With considerable expertise, an attractive infrastructure and all-important tax breaks, the life sciences are the biggest source of foreign investment in Ireland, with the pharmaceutical and biotech industries bringing in the bulk of the €2.6bn the region saw in capital investment projects over 2006.

Related news

Show more

Related products

show more

Strategies to Achieve Successful Approval & Launch

Strategies to Achieve Successful Approval & Launch

Catalent Pharma Solutions | 03-Sep-2020 | Data Sheet

There are several key considerations to how companies should approach commercial-scale manufacturing that may aid the success of their biologic’s launch...

Single-Pass Tangential Flow Filtration

Single-Pass Tangential Flow Filtration

BioContinuum™ Platform - MilliporeSigma | 01-Aug-2020 | Application Note

Tangential flow filtration (TFF) is widely used in the biopharmaceutical industry for downstream processing applications. Typical TFF steps concentrate...

Follow us

Products

View more

Webinars